Galapagos Genomics N (GLPGF) 49.9000 $GLPGF
Galapagos on deck for IPO
Seeking Alpha - at Seeking Alpha - Fri May 08, 12:15PM CDT
JNJ: 103.42 (+1.12), ABBV: 65.61 (-0.38)
Galapagos Moves Towards RA Deal But A Dark Horse Remains On The Horizon
EP Vantage - Seeking Alpha - Thu Apr 16, 3:57PM CDT
Galapagos ’ ( OTC:GLPGF , OTCPK:GLPYY ) oral rheumatoid arthritis drug GLPG0634 has cleared the first obstacle in the path to a full-blown licensing deal with AbbVie (NYSE: ABBV ) , hitting the primary endpoint of a crucial phase IIb trial....
Galapagos to list ADSs on Nasdaq
Seeking Alpha - at Seeking Alpha - Thu Apr 16, 8:35AM CDT
Galapagos JAK-1 inhibitor successful in Phase 2 rheumatoid arthritis study
Seeking Alpha - at Seeking Alpha - Tue Apr 14, 4:17PM CDT
Galapagos and Janssen part ways in inflammation alliance
Seeking Alpha - at Seeking Alpha - Tue Mar 17, 6:58AM CDT
JNJ: 103.42 (+1.12)
Seeking Alpha's Biotech Weekly: Crush-Proof Pfizer, Achillion's HCV Crusher, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 13, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
VRX: 225.43 (+0.80), ACT: 295.76 (-0.84), MDT: 77.47 (+1.05), XON: 41.17 (+1.09), CTIC: 1.78 (-0.02), PFNX: 15.87 (+2.17), JNJ: 103.42 (+1.12), ANTM: 163.25 (+1.88), NVAX: 8.72 (+0.18), SHPG: 254.71 (+0.26), ABBV: 65.61 (-0.38), TBPH: 14.35 (-0.34), SNY: 50.40 (-0.12), ALQA: 4.40 (-0.08), REGN: 496.74 (+7.73), ONCY: 0.71 (unch), PFE: 33.98 (-0.01), SLXP: 172.96 (+0.15), EPRS: 5.94 (+0.33), AMGN: 163.44 (+1.08), NKTR: 11.32 (+0.19), ZTS: 46.73 (+0.24), GILD: 111.00 (+1.70), ACHN: 11.03 (+1.46), GERN: 3.88 (-0.01)
Galapagos awarded €1.6M grant to develop Hep B therapies
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 6:44AM CST
Galapagos earns milestone from AbbVie
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 7:09AM CST
ABBV: 65.61 (-0.38)
Molecular Biology Meets Finance: MLV's George Zavoico On Ebola's Silver Lining
Life Sciences Report - Seeking Alpha - Thu Nov 13, 6:59AM CST
A working knowledge of molecular biology is essential for a biotech investor, but it helps when someone with deep knowledge of science and medicine can bring understanding to the people who commit capital to growth ideas. George Zavoico of MLV &...
CERS: 4.60 (-0.01), AGEN: 6.80 (-0.10), NVAX: 8.72 (+0.18), ALXN: 163.16 (+2.60), PPHM: 1.36 (-0.01), THLD: 4.09 (+0.15), GSK: 44.66 (-0.11), OMER: 20.99 (+0.11)
Galapagos - AbbVie's Best Bet For Staying Market Leader In Rheumatoid Arthritis Post Humira?
SNJBiostoxx - at Seeking Alpha - Tue Nov 11, 2:45PM CST
ABBV: 65.61 (-0.38)
Galapagos on deck for IPO
Seeking Alpha - at Seeking Alpha - Fri May 08, 12:15PM CDT
JNJ: 103.42 (+1.12), ABBV: 65.61 (-0.38)
Galapagos Moves Towards RA Deal But A Dark Horse Remains On The Horizon
EP Vantage - Seeking Alpha - Thu Apr 16, 3:57PM CDT
Galapagos ’ ( OTC:GLPGF , OTCPK:GLPYY ) oral rheumatoid arthritis drug GLPG0634 has cleared the first obstacle in the path to a full-blown licensing deal with AbbVie (NYSE: ABBV ) , hitting the primary endpoint of a crucial phase IIb trial....
Galapagos to list ADSs on Nasdaq
Seeking Alpha - at Seeking Alpha - Thu Apr 16, 8:35AM CDT
Galapagos JAK-1 inhibitor successful in Phase 2 rheumatoid arthritis study
Seeking Alpha - at Seeking Alpha - Tue Apr 14, 4:17PM CDT
Galapagos and Janssen part ways in inflammation alliance
Seeking Alpha - at Seeking Alpha - Tue Mar 17, 6:58AM CDT
JNJ: 103.42 (+1.12)
Seeking Alpha's Biotech Weekly: Crush-Proof Pfizer, Achillion's HCV Crusher, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 13, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
VRX: 225.43 (+0.80), ACT: 295.76 (-0.84), MDT: 77.47 (+1.05), XON: 41.17 (+1.09), CTIC: 1.78 (-0.02), PFNX: 15.87 (+2.17), JNJ: 103.42 (+1.12), ANTM: 163.25 (+1.88), NVAX: 8.72 (+0.18), SHPG: 254.71 (+0.26), ABBV: 65.61 (-0.38), TBPH: 14.35 (-0.34), SNY: 50.40 (-0.12), ALQA: 4.40 (-0.08), REGN: 496.74 (+7.73), ONCY: 0.71 (unch), PFE: 33.98 (-0.01), SLXP: 172.96 (+0.15), EPRS: 5.94 (+0.33), AMGN: 163.44 (+1.08), NKTR: 11.32 (+0.19), ZTS: 46.73 (+0.24), GILD: 111.00 (+1.70), ACHN: 11.03 (+1.46), GERN: 3.88 (-0.01)
Galapagos awarded €1.6M grant to develop Hep B therapies
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 6:44AM CST
Galapagos earns milestone from AbbVie
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 7:09AM CST
ABBV: 65.61 (-0.38)
Molecular Biology Meets Finance: MLV's George Zavoico On Ebola's Silver Lining
Life Sciences Report - Seeking Alpha - Thu Nov 13, 6:59AM CST
A working knowledge of molecular biology is essential for a biotech investor, but it helps when someone with deep knowledge of science and medicine can bring understanding to the people who commit capital to growth ideas. George Zavoico of MLV &...
CERS: 4.60 (-0.01), AGEN: 6.80 (-0.10), NVAX: 8.72 (+0.18), ALXN: 163.16 (+2.60), PPHM: 1.36 (-0.01), THLD: 4.09 (+0.15), GSK: 44.66 (-0.11), OMER: 20.99 (+0.11)
Galapagos - AbbVie's Best Bet For Staying Market Leader In Rheumatoid Arthritis Post Humira?
SNJBiostoxx - at Seeking Alpha - Tue Nov 11, 2:45PM CST
ABBV: 65.61 (-0.38)
